MarketCap
Facebook
X
TelegramQuarterly report 2025-Q2
added 07-31-2025
Apellis Pharmaceuticals Cash Conversion Cycle 2011-2026 | APLS
Annual Cash Conversion Cycle Apellis Pharmaceuticals
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 110 | 98.5 | 43.1 | 27.7 | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 110 | 27.7 | 69.9 |
Quarterly Cash Conversion Cycle Apellis Pharmaceuticals
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 115 | 137 | - | 135 | 131 | 126 | - | 116 | 68.4 | 39.9 | - | 32.3 | 38.7 | 52.1 | - | 34.2 | 52.7 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 137 | 32.3 | 82.9 |
Cash Conversion Cycle of other stocks in the Biotechnology industry
| Issuer | Cash Conversion Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Alnylam Pharmaceuticals
ALNY
|
30.6 | $ 322.7 | 0.84 % | $ 41.2 B |  USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
25 | - | -15.15 % | $ 60.3 M |  Britain |
 |
Amarin Corporation plc
AMRN
|
157 | $ 15.14 | 2.61 % | $ 6.17 B |  Irlanda |
 |
Acasti Pharma
ACST
|
1.97 | - | 4.01 % | $ 150 M |  Canada |
 |
I-Mab
IMAB
|
-1.97 K | - | - | $ 866 M |  China |
 |
Aptorum Group Limited
APM
|
-400 | $ 0.84 | 2.78 % | $ 4.58 M | China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
12.8 | - | - | $ 40.3 B | USA |
 |
Adagene
ADAG
|
53.8 | $ 2.95 | 10.57 % | $ 166 M | China |
 |
Midatech Pharma plc
MTP
|
82.8 | - | -18.52 % | $ 27.3 M | Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
17 | - | -1.52 % | $ 24.7 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-2.85 K | - | -11.43 % | $ 502 K | USA |
 |
Acorda Therapeutics
ACOR
|
117 | - | -24.86 % | $ 820 K | USA |
 |
Compugen Ltd.
CGEN
|
-123 | $ 1.79 | 4.39 % | $ 160 M |  Israel |
 |
Albireo Pharma
ALBO
|
-1.55 K | - | -0.23 % | $ 916 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
104 | - | - | - |  Russia |
 |
Aptinyx
APTX
|
46.9 | - | -39.0 % | $ 4.57 M | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
-186 | $ 41.27 | -0.1 % | $ 4.26 B | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
54.2 | $ 24.19 | -1.06 % | $ 2.87 B | USA |
 |
Arena Pharmaceuticals
ARNA
|
946 | - | -6.81 % | $ 3.04 B | USA |
 |
Champions Oncology
CSBR
|
1.94 | $ 6.41 | -2.14 % | $ 87.6 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
59 | - | 17.91 % | $ 11.1 M | USA |
 |
Aeterna Zentaris
AEZS
|
-34.3 K | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
-8.96 K | - | -10.17 % | $ 12.2 K | USA |
 |
Precision BioSciences
DTIL
|
6.07 | $ 3.77 | -1.05 % | $ 14.5 M | USA |
 |
Amneal Pharmaceuticals
AMRX
|
123 | $ 14.73 | 1.41 % | $ 4.55 B | USA |
 |
Codexis
CDXS
|
-48.2 | $ 1.27 | -1.55 % | $ 93.2 M | USA |